A
Actym
Biotech developing truly disruptive Immuno-oncology platform
About Actym
Actym Therapeutics is a pioneering biotechnology company focused on developing innovative cancer therapies. The company harnesses genetically modified bacterial vehicles to safely introduce therapeutic payloads that activate the immune response within the tumor microenvironment (TME). This novel drug modality is designed to target and enrich in the TME, delivering potent and synergistic payloads specifically to tumors. Actym Therapeutics primarily serves cancer patients, aiming to overcome the hostile tumor immune microenvironment to bring durable benefits. Operating in the oncology market, the company collaborates with scientists, potential partners, and journalists to advance its mission. Actym's business model revolves around research and development, leveraging scientific talents in molecular and microbiology, cancer immunology, and manufacturing. Revenue is generated through partnerships, grants, and potentially future product sales. Keywords: cancer therapy, genetically modified bacteria, immune response, tumor microenvironment, oncology, biotechnology, innovative therapies, research and development, molecular biology, cancer immunology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- San Francisco, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 66.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Latest news
Press, funding announcements and product moves mentioning Actym.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2023 | $26M | $170M | JLo Ventures · Panacea Venture · GKCC · Boehringer Ingelheim Venture Fund | ↗ |
| EARLY VCOther financing | Jul 2023 | $11M | $170M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Actym is 4.8K monthly website visits, up 269.2% over the last three months. Actym's team declined 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Intellectus Partners
Series A6 investors entered at this stage
Boehringer Ingelheim Venture Fund
Korea Investment Partners
Illumina Ventures
Panacea Venture- JVJLo Ventures
- GKGKCC
Other known investors1 additional known investor
University of California, Berkeley
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Actym on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Actym’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.